Cases of uterine sarcoma in women receiving tamoxifen citrate (Nolvadex, AstraZeneca) have prompted a "Dear Health Professional" letter, black-box warnings on labeling, and publication of a letter to the editor in the New England Journal of Medicine from FDA officials.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

NEW WARNING: Uterine sarcoma linked with long-term tamoxifen use

Newsletter